Predicine was founded in Silicon Valley, California in 2015.
Innovating the next-generation liquid biopsy technology, we've established an integrated "one-stop-shop" biomarker service platform and conducted big data analysis to enable precision medicine in personalized cancer care and global drug development.
Innovating the next-generation liquid biopsy technology, we've established an integrated "one-stop-shop" biomarker service platform and conducted big data analysis to enable precision medicine in personalized cancer care and global drug development.
Gene RADAR: ctRNA and ctDNA single Molecule Digital Reading
a patented ctRNA + ctDNA combination blood test
Liquid biopsies, or blood tests to detect molecular biomarkers of cancer cells, have traditionally tested only at patients' circulating DNA level. However, many clinically meaningful cancer variants exist at both the DNA and RNA level, and some occur only at the RNA level such as RNA splicing. By examining cfDNA and cfRNA released by cancer cells into blood vessels simultaneously, Gene RADAR boosts detection sensitivity and specificity for genes of interest in circulation.
Product Portfolio
|
Clinical Research Solution
|
Clinical Treatment Solution
|
Health Management Solution
|
|
|
|
|
PrediSeq
For Global Pharmaceutical Customers Accelerate Clinical Trials Support Drug Development Vertical Divider
|
PrediAct
For Patients Actionable Targets Precision Guidance For Treatment Vertical Divider
|
PrediScreen
For People at Risk Early Cancer Detection Health Management Vertical Divider
|
News & Events
- Dec 3, 2018 - Congruence Study Between Two ctDNA Liquid Biopsy Testing in mBC Patients and Prognostic Value in Combination with CTCs, Investigators to Report at SABCS 2018
- Oct 18, 2018 -- Predicine Establishes Dual CAP Accreditation for its Genomic Sequencing Laboratories in US and China to Support Global Clinical Trials
- Sept 20, 2018 -- Predicine and Flagship Biosciences Partner to Support Global Biomarker Development
- Sept 20-22, 2018 -- CSCO 2018
- Aug 20-24, 2018 -- Next Generation Summit 2018 (Washington D.C)
- June 11-13, 2018 — Biomarkers & Immuno-Oncology World Congress 2018 (Boston) — Predicine Oral Presentation
- June 3, 2018 — Clinical Oncologist Daily, "Precision Clinical Trials in IO" - Interview article at ASCO
- June 2, 2018 — 20th SAPA-NE Annual Conference (Boston), "Transforming Immuno-Oncology with RNA+DNA Liquid Biopsy Solutions" - Predicine Plenary Oral Presentation
- June 1-5, 2018 - ASCO Annual Meeting (Chicago) - Predicine Satellite Symposium, Booth and Poster
- May 18-21, 2018 - AUA2018 Annual Conference (San Francisco) - Predicine Booth
- April 30, 2018 - Predicine Launches PredicineATLAS, a 600-gene Blood-based TMB Panel to Accelerate Immuno-Oncology Clinical Trials - News in BioSpace
- April 14-18, 2018 - AACR Annual Meeting (Chicago) - Predicine Satellite Symposium, Booth and Posters
- March 30-31, 2018 - BIT's Annual International Congress of Biotherapy-2018 (Beijing) - Predicine Plenary Speaker
- February 11-16, 2018 - 2017 Molecular Med TriCon Annual Meeting in San Francisco, USA - Predicine Booth
- February 10, 2018 - The 2nd Annual SABPA Frontiers in Therapeutics and Diagnostics (FTD) Forum (San Diego) - Predicine Panel Speaker
- February 8-10, 2018. ASCO GU Annual Conference (San Francisco) - Predicine Both
- February 7, 2018 - Harbin establishes gene innovation and development center, Harbin, China. - Predicine Plenary Speaker
- December 8-11, 2017 - 2017 ASH Annual Meeting (Atlanta) - Predicine Booth
- September 26-30, 2017 - 2017 CSCO (Chinese Society of Clinical Oncology) Annual Meeting at Xiamen, China - Predicine Satellite Symposium, Booth and Posters
- September 8-12, 2017 - 2017 ESMO (European Society for Medical Oncology) Annual Meeting in Madrid, Spain - Predicine Booth
- June 21-23, 2017 — Second Annual Liquid Biopsy Summit (San Francisco) — Predicine Oral Presentation
- June 24, 2017 — BioPacific Conference 2017 (CABS) — Predicine Booth
- June 3, 2017 — Clinical Oncologist Daily "Liquid Biopsy to Accelerate Patient Enrollment in Clinical Trials"
- June 2-6, 2017 — 2017 ASCO Annual Meeting (Chicago) — Predicine Booth, Wine Reception & Predi-Trial Launch
- April 1-5, 2017 — AACR 2017 Annual Meeting (Washington DC) — Predicine Booth, Posters, Reception
- March 25, 2017 — CABS Workshop “Precision Medicine for Oncology and Immunology” — Predicine Talk and Booth
- March 18, 2017 — CABS Workshop “NGS for Cancer and Autoimmune disease” — Predicine Booth
- February 20-22, 2017 — The Molecular Medicine Tri Conference 2017 (San Francisco) — Predicine Talk and Booth
- February 16-18, 2017 — 2017 Genitourinary Cancers Symposium (ASCO-GU) — Predicine Booth and new product release
- February 15, 2017 — GEN Report — Tumor Biomarkers Guide Immunotherapy